会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • AUTOPHILIC ANTIBODIES
    • 自动抗体
    • WO2009002939A3
    • 2009-04-23
    • PCT/US2008067917
    • 2008-06-23
    • INNEXUS BIOTECHNOLOGY INTERNATKOHLER HEINZAMICK JEANRUSS MICHAEL A
    • KOHLER HEINZAMICK JEANRUSS MICHAEL A
    • C07K16/18A61K39/395
    • C07K19/00A61K47/6811A61K47/6843C07K2317/732C07K2317/734
    • Autophilic antibodies including an immunoglobulin component and an autophilic peptide fused thereto are provided according to embodiments of the present invention. Particular autophilic antibodies described herein include a chimeric gamma immunoglobulin heavy chain and autophilic peptide expressed as a fusion protein. Preferably the autophilic peptide is expressed at the C-terminus of the immunoglobulin component. Expression vectors according to embodiments of the present invention for use in generating autophilic antibodies are provided which include a first nucleic acid sequence encoding an autophilic peptide, operably linked to a transcription promoter. In particular embodiments, a second nucleic acid sequence encoding a chimeric heavy chain of an immunoglobulin operably linked to the transcription promoter and connected to the first nucleic acid sequence such that expression of the first and second nucleic acid sequences produces a fusion protein of the chimeric heavy chain and the autophilic peptide.
    • 根据本发明的实施方案提供了包括免疫球蛋白组分和与其融合的自亲自肽的亲电抗体。 本文所述的特定的自亲免疫抗体包括嵌合γ免疫球蛋白重链和表达为融合蛋白的自噬肽。 优选地,所述自噬肽在所述免疫球蛋白组分的C末端表达。 提供了根据本发明实施方案用于产生自亲免疫抗体的表达载体,其包括编码与转录启动子有效连接的自噬肽的第一核酸序列。 在具体实施方案中,编码免疫球蛋白嵌合重链的第二核酸序列,其可操作地连接到转录启动子并与第一核酸序列连接,使得第一和第二核酸序列的表达产生嵌合重链的融合蛋白 链和自噬肽。
    • 9. 发明申请
    • FUSION PROTEINS OF BIOLOGICALLY ACTIVE PEPTIDES AND ANTIBODIES
    • 生物活性肽和抗体的融合蛋白
    • WO02097041A2
    • 2002-12-05
    • PCT/US0216651
    • 2002-05-29
    • IMMPHERON INCINNEXUS CORPKOHLER HEINZMORGAN CHARLES
    • KOHLER HEINZMORGAN CHARLES
    • A61K39/00C07K14/47C07K14/77C07K16/00C07K16/42C12N
    • C07K14/472A61K39/00A61K2039/505C07K14/77C07K16/00C07K16/4208C07K16/4266C07K2319/00
    • A fusion protein is made up of (1) an antibody and (2) a peptide having a biological activity such as immuno-stimulatory, membrane transport and homophilic activities wherein the peptide is connected to the antibody at a site that does not interfere with antigen binding of the antibody. The fusion protein is made by the steps of creating a fusion gene including a nucleic acid sequence encoding an antibody and a nucleic acid sequence encoding the peptide, wherein the nucleic acid sequence encoding the peptide is located inside the nucleic acid sequence encoding the antibody at a site wherein, when the fusion is expressed, the fusion protein created thereby comprises the antibody and the peptide, wherein the peptide is connected to the antibody at a site that does not interfere with antigen binding of the antibody, and expressing the fusion gene to create the fusion protein. The peptide may be flanked by loop-forming or conformation-conferring sequences.
    • 融合蛋白由(1)抗体和(2)具有生物学活性的肽,例如免疫刺激,膜转运和亲和活性组成,其中肽在不干扰抗原的位点连接到抗体 抗体的结合。 融合蛋白是通过产生包含编码抗体的核酸序列和编码该肽的核酸序列的融合基因的步骤制备的,其中编码该肽的核酸序列位于编码该抗体的核酸序列的内部 其中,当融合表达时,由此产生的融合蛋白包含抗体和肽,其中肽在不干扰抗体的抗原结合的位点处连接到抗体,并表达融合基因以产生 融合蛋白。 肽可以侧接于环形成或构象赋予序列。